190 related articles for article (PubMed ID: 20592032)
21. Human IgG lacking effector functions demonstrate lower FcRn-binding and reduced transplacental transport.
Stapleton NM; Armstrong-Fisher SS; Andersen JT; van der Schoot CE; Porter C; Page KR; Falconer D; de Haas M; Williamson LM; Clark MR; Vidarsson G; Armour KL
Mol Immunol; 2018 Mar; 95():1-9. PubMed ID: 29367080
[TBL] [Abstract][Full Text] [Related]
22. V Region of IgG Controls the Molecular Properties of the Binding Site for Neonatal Fc Receptor.
Rossini S; Noé R; Daventure V; Lecerf M; Justesen S; Dimitrov JD
J Immunol; 2020 Nov; 205(10):2850-2860. PubMed ID: 33077645
[TBL] [Abstract][Full Text] [Related]
23. Structural basis of pH-dependent antibody binding by the neonatal Fc receptor.
Vaughn DE; Bjorkman PJ
Structure; 1998 Jan; 6(1):63-73. PubMed ID: 9493268
[TBL] [Abstract][Full Text] [Related]
24. Antigen physiochemical properties allosterically effect the IgG Fc-region and Fc neonatal receptor affinity.
Sun Y; Estevez A; Schlothauer T; Wecksler AT
MAbs; 2020; 12(1):1802135. PubMed ID: 32795110
[TBL] [Abstract][Full Text] [Related]
25. The multiple facets of FcRn in immunity.
Stapleton NM; Einarsdóttir HK; Stemerding AM; Vidarsson G
Immunol Rev; 2015 Nov; 268(1):253-68. PubMed ID: 26497526
[TBL] [Abstract][Full Text] [Related]
26. The X-Ray Crystallographic Structure of the Human Neonatal Fc Receptor at Acidic pH Gives Insights into pH-Dependent Conformational Changes.
Taha M; Ward SE; Nam HJ
Protein Pept Lett; 2016; 23(6):525-9. PubMed ID: 27041699
[TBL] [Abstract][Full Text] [Related]
27. In Translation: FcRn across the Therapeutic Spectrum.
Qi T; Cao Y
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33802650
[TBL] [Abstract][Full Text] [Related]
28. Importance of neonatal FcR in regulating the serum half-life of therapeutic proteins containing the Fc domain of human IgG1: a comparative study of the affinity of monoclonal antibodies and Fc-fusion proteins to human neonatal FcR.
Suzuki T; Ishii-Watabe A; Tada M; Kobayashi T; Kanayasu-Toyoda T; Kawanishi T; Yamaguchi T
J Immunol; 2010 Feb; 184(4):1968-76. PubMed ID: 20083659
[TBL] [Abstract][Full Text] [Related]
29. Ca2+-dependent calmodulin binding to FcRn affects immunoglobulin G transport in the transcytotic pathway.
Dickinson BL; Claypool SM; D'Angelo JA; Aiken ML; Venu N; Yen EH; Wagner JS; Borawski JA; Pierce AT; Hershberg R; Blumberg RS; Lencer WI
Mol Biol Cell; 2008 Jan; 19(1):414-23. PubMed ID: 18003977
[TBL] [Abstract][Full Text] [Related]
30. Inhibitors of the FcRn:IgG protein-protein interaction.
Low SC; Mezo AR
AAPS J; 2009 Sep; 11(3):432-4. PubMed ID: 19499344
[TBL] [Abstract][Full Text] [Related]
31. Effect of individual Fc methionine oxidation on FcRn binding: Met252 oxidation impairs FcRn binding more profoundly than Met428 oxidation.
Gao X; Ji JA; Veeravalli K; Wang YJ; Zhang T; Mcgreevy W; Zheng K; Kelley RF; Laird MW; Liu J; Cromwell M
J Pharm Sci; 2015 Feb; 104(2):368-77. PubMed ID: 25175600
[TBL] [Abstract][Full Text] [Related]
32. Qualification of a homogeneous cell-based neonatal Fc receptor (FcRn) binding assay and its application to studies on Fc functionality of IgG-based therapeutics.
Mathur A; Arora T; Liu L; Crouse-Zeineddini J; Mukku V
J Immunol Methods; 2013 Apr; 390(1-2):81-91. PubMed ID: 23384837
[TBL] [Abstract][Full Text] [Related]
33. Investigating the interaction between the neonatal Fc receptor and monoclonal antibody variants by hydrogen/deuterium exchange mass spectrometry.
Jensen PF; Larraillet V; Schlothauer T; Kettenberger H; Hilger M; Rand KD
Mol Cell Proteomics; 2015 Jan; 14(1):148-61. PubMed ID: 25378534
[TBL] [Abstract][Full Text] [Related]
34. The conserved histidine 166 residue of the human neonatal Fc receptor heavy chain is critical for the pH-dependent binding to albumin.
Andersen JT; Dee Qian J; Sandlie I
Eur J Immunol; 2006 Nov; 36(11):3044-51. PubMed ID: 17048273
[TBL] [Abstract][Full Text] [Related]
35. FcRn: the neonatal Fc receptor comes of age.
Roopenian DC; Akilesh S
Nat Rev Immunol; 2007 Sep; 7(9):715-25. PubMed ID: 17703228
[TBL] [Abstract][Full Text] [Related]
36. Multivalent immune complexes divert FcRn to lysosomes by exclusion from recycling sorting tubules.
Weflen AW; Baier N; Tang QJ; Van den Hof M; Blumberg RS; Lencer WI; Massol RH
Mol Biol Cell; 2013 Aug; 24(15):2398-405. PubMed ID: 23741050
[TBL] [Abstract][Full Text] [Related]
37. Membrane-anchored human FcRn can oligomerize in the absence of IgG.
Praetor A; Jones RM; Wong WL; Hunziker W
J Mol Biol; 2002 Aug; 321(2):277-84. PubMed ID: 12144784
[TBL] [Abstract][Full Text] [Related]
38. Neonatal Fc receptor (FcRn): a novel target for therapeutic antibodies and antibody engineering.
Wang Y; Tian Z; Thirumalai D; Zhang X
J Drug Target; 2014 May; 22(4):269-78. PubMed ID: 24404896
[TBL] [Abstract][Full Text] [Related]
39. Monoclonal antibodies with identical Fc sequences can bind to FcRn differentially with pharmacokinetic consequences.
Wang W; Lu P; Fang Y; Hamuro L; Pittman T; Carr B; Hochman J; Prueksaritanont T
Drug Metab Dispos; 2011 Sep; 39(9):1469-77. PubMed ID: 21610128
[TBL] [Abstract][Full Text] [Related]
40. Engineering a monomeric Fc domain modality by N-glycosylation for the half-life extension of biotherapeutics.
Ishino T; Wang M; Mosyak L; Tam A; Duan W; Svenson K; Joyce A; O'Hara DM; Lin L; Somers WS; Kriz R
J Biol Chem; 2013 Jun; 288(23):16529-16537. PubMed ID: 23615911
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
